MARKET

NBSE

NBSE

NeuBase Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.650
-0.130
-7.30%
Opening 15:18 01/20 EST
OPEN
1.770
PREV CLOSE
1.780
HIGH
1.900
LOW
1.610
VOLUME
196.62K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
1.610
MARKET CAP
54.00M
P/E (TTM)
-1.7937
1D
5D
1M
3M
1Y
5Y
NeuBase Therapeutics hires new chief financial officer
NeuBase Therapeutics, a Pittsburgh-based developer of genetic medicines, announced that it has hired Todd Branning as its new chief financial officer.
American City Business Journals · 01/11 16:34
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 01/11 13:20
NeuBase Therapeutics names Phathom's Todd Branning as new CFO
NeuBase Therapeutics (NASDAQ:NBSE) appoints Todd P. Branning as the company's new chief financial officer.  Prior to joining NeuBase, Branning served as CFO of Phathom Pharmaceuticals (NASDAQ:PHAT) and has previously served as Senior Vice President,
Seekingalpha · 01/10 21:10
5 Stocks To Watch For December 27, 2021
Some of the stocks that may grab investor focus today are:
Benzinga · 12/27/2021 09:37
NeuBase Therapeutics reports FY results
NeuBase Therapeutics (NASDAQ:NBSE): FY GAAP EPS of -$0.93. As of September 30, 2021, the company had cash and cash equivalents of ~$52.9M, compared with ~$32.0M as of September 30, 2020.
Seekingalpha · 12/27/2021 09:26
BRIEF-Neubase Therapeutics Reports Business Update And Financial Results For Fiscal Year 2021
reuters.com · 12/23/2021 21:03
EXCLUSIVE: NeuBase Therapeutics Chairman & CEO, Dietrich Stephan, PhD Now Interviewing On Benzinga' Live Tv
Click To Tune In Here... https://www.youtube.com/watch?v=-NFQEIRCg0Q
Click To Tune In Here...  · 11/24/2021 17:18
Quite a few insiders invested in NeuBase Therapeutics, Inc. (NASDAQ:NBSE) last year which is positive news for shareholders
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 11/01/2021 17:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBSE. Analyze the recent business situations of NeuBase Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NBSE stock price target is 16.25 with a high estimate of 18.00 and a low estimate of 15.00.
High18.00
Average16.25
Low15.00
Current 1.650
EPS
Actual
Estimate
-0.23-0.17-0.12-0.06
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 65
Institutional Holdings: 10.16M
% Owned: 31.05%
Shares Outstanding: 32.73M
TypeInstitutionsShares
Increased
12
373.86K
New
1
75.00K
Decreased
18
605.84K
Sold Out
12
468.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.16%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dietrich Stephan
Chief Financial Officer
Todd Branning
Chief Operating Officer
William Mann
Other
Sandra Rojas-Caro
Director
Eric Ende
Independent Director
Dov Goldstein
Independent Director
Gerald McDougall
Independent Director
Franklyn Prendergast
Independent Director
Eric Richman
No Data
About NBSE
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBSE stock methods without spending real money on the virtual paper trading platform.